NMR structural characterization of peptide inhibitors bound to the hepatitis C virus NS3 protease: Design of a new P2 substituent

被引:51
作者
Goudreau, N [1 ]
Cameron, DR
Bonneau, P
Gorys, V
Plouffe, C
Poirier, M
Lamarre, D
Llinas-Brunet, M
机构
[1] Boehringer Ingelheim Canada Ltd, Res & Dev, Dept Chem, Laval, PQ H7S 2G5, Canada
[2] Boehringer Ingelheim Canada Ltd, Res & Dev, Dept Biol Sci, Laval, PQ H7S 2G5, Canada
关键词
D O I
10.1021/jm0303002
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A comparative NMR conformational analysis of three distinct tetrapeptide inhibitors of the Hepatitis C NS3 protease that differ at the 4-aryloxy-substituted P2 proline position was undertaken. Specifically, transferred nuclear Overhauser effect experiments in combination with restrained systematic conformational searches were used to characterize the orientation of the P2 aryl substituents of these inhibitors when bound to the NS3 protease. Differences between free and bound conformations were also investigated. Analysis of the results allowed the design of a new P2 aromatic substituent, which significantly increased the potency of our inhibitors. The bound conformation of a specific competitive inhibitor having this novel P2 substituent is also described, along with a model of this inhibitor bound to the NS3 protease. This NS3 protease/inhibitor complex model also supports a hypothetical stabilization role for the P2 residue of the substrates and/or inhibitors and further elucidates the subtle details of the binding of the P2 residue of substrate-based inhibitors.
引用
收藏
页码:123 / 132
页数:10
相关论文
共 43 条
  • [21] Studies on the C-terminal of hexapeptide inhibitors of the hepatitis C virus serine protease
    Llinàs-Brunet, M
    Bailey, M
    Déziel, R
    Fazal, G
    Gorys, V
    Goulet, S
    Halmos, T
    Maurice, R
    Poirier, M
    Poupart, MA
    Rancourt, J
    Thibeault, D
    Wernic, D
    Lamarre, D
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (19) : 2719 - 2724
  • [22] Peptide-based inhibitors of the hepatitis C virus serine protease
    Llinàs-Brunet, M
    Bailey, M
    Fazal, G
    Goulet, S
    Halmos, T
    Laplante, S
    Maurice, R
    Poirier, M
    Poupart, MA
    Thibeault, D
    Wernic, D
    Lamarre, D
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (13) : 1713 - 1718
  • [23] LLINASBRUNET M, 2000, Patent No. 0009543
  • [24] The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site
    Love, RA
    Parge, HE
    Wickersham, JA
    Hostomsky, Z
    Habuka, N
    Moomaw, EW
    Adachi, T
    Hostomska, Z
    [J]. CELL, 1996, 87 (02) : 331 - 342
  • [25] Marchetti A, 1999, SYNLETT, P1000
  • [26] Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
    McHutchison, JG
    Gordon, SC
    Schiff, ER
    Shiffman, ML
    Lee, WM
    Rustgi, VK
    Goodman, ZD
    Ling, MH
    Cort, S
    Albrecht, JK
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (21) : 1485 - 1492
  • [27] NI F, 1994, PROG NUCL MAG RES SP, V26, P517, DOI 10.1016/0079-6565(94)90000-0
  • [28] Solid-phase synthesis of peptidomimetic inhibitors for the hepatitis C virus NS3 protease
    Poupart, MA
    Cameron, DR
    Chabot, C
    Ghiro, E
    Goudreau, N
    Goulet, S
    Poirier, M
    Tsantrizos, YS
    [J]. JOURNAL OF ORGANIC CHEMISTRY, 2001, 66 (14) : 4743 - 4751
  • [29] RANCOURT J, UNPUB
  • [30] ON SIZE OF ACTIVE SITE IN PROTEASES .I. PAPAIN
    SCHECHTER, I
    BERGER, A
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1967, 27 (02) : 157 - +